Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats

ConclusionsBoth in vitro and in vivo results demonstrated that a drug ‐drug interaction between avitinib and osimertinib occurred and more attention should be paid when avitinib and osimertinib are synchronously administered in clinic.Key pointsSignificant findings of the studyOsimertinib is the only market available third ‐generation EGFR‐TKI and it has been reported that some drugs could have drug‐drug interactions with it.What this study addsFor the first time, we systematically investigated the effect of avitinib, one newly developed third ‐generation EGFR‐TKI, on the pharmacokinetics of osimertinib both in vitro and in vivo using a rat model.

Source: Thoracic Cancer - August 18, 2020 Category: Cancer & Oncology Authors: Qingjun Wu, Hui Jiang, Shuanghu Wang, Dapeng Dai, Feifei Chen, Deru Meng, Peiwu Geng, Hongfeng Tong, Yunfang Zhou, Debiao Pan, Quan Zhou, Chunjie Wang Tags: ORIGINAL ARTICLE Source Type: research